Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Other Accumulated Expenses (2017 - 2026)

Neurocrine Biosciences filings provide 14 years of Other Accumulated Expenses readings, the most recent being $69.1 million for Q4 2025.

  • On a quarterly basis, Other Accumulated Expenses rose 49.89% to $69.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $69.1 million, a 49.89% increase, with the full-year FY2025 number at $69.1 million, up 49.89% from a year prior.
  • Other Accumulated Expenses hit $69.1 million in Q4 2025 for Neurocrine Biosciences, up from $53.7 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $69.1 million in Q4 2025 to a low of $17.6 million in Q1 2022.
  • Median Other Accumulated Expenses over the past 5 years was $21.6 million (2021), compared with a mean of $31.9 million.
  • Biggest five-year swings in Other Accumulated Expenses: dropped 9.5% in 2022 and later surged 99.46% in 2024.
  • Neurocrine Biosciences' Other Accumulated Expenses stood at $20.0 million in 2021, then increased by 3.5% to $20.7 million in 2022, then skyrocketed by 73.43% to $35.9 million in 2023, then grew by 28.41% to $46.1 million in 2024, then soared by 49.89% to $69.1 million in 2025.
  • The last three reported values for Other Accumulated Expenses were $69.1 million (Q4 2025), $53.7 million (Q3 2025), and $56.8 million (Q2 2025) per Business Quant data.